Nivolumab for newly diagnosed nasopharyngeal cancer
Treatments studied
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial tests whether the immunotherapy drug nivolumab (Opdivo) can help treat nasopharyngeal cancer in both children and adults. It is for people who have just been diagnosed and have not yet received any cancer treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are newly diagnosed with nasopharyngeal cancer (not a return of the cancer).
- Your cancer is at a certain stage: stage II or higher if you are 25 or younger, or stage III or IV if you are older than 25.
- You have not had any chemotherapy or radiation therapy for this cancer before.
- You have enough tumor tissue (from a biopsy) to send for testing.
- You do not have an active autoimmune disease (except well-controlled thyroid or skin issues) and are not taking strong immune-suppressing drugs.
- Your blood counts, kidney and liver function are within certain healthy ranges (specific tests will be done).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies nivolumab (an immune therapy) for nasopharyngeal cancer that grew or returned after platinum chemotherapy. It aims to shrink tumors or slow cancer growth after standard treatment hasn’t worked.
This trial tests a new treatment plan for a specific type of advanced nasopharyngeal cancer. It combines chemotherapy and radiation to see if it can improve outcomes for people with high-risk stage III disease.
This Phase 3 trial tests a stronger treatment approach for people with locally advanced nasopharyngeal cancer whose EBV “DNA” (a cancer-related virus signal in blood) does not go away after one cycle of chemotherapy. It may help improve outcomes by changing treatment based on how the cancer responds early.
This trial tests a shorter course of chemotherapy combined with an immunotherapy drug (camrelizumab) for people with advanced nasopharyngeal cancer that hasn't spread to distant organs. The goal is to see if this approach works well while reducing treatment side effects.
This trial tests whether a lower dose of radiation can safely treat stage III nasopharyngeal cancer if you have already responded well to initial chemotherapy plus immunotherapy (Camrelizumab). The goal is to reduce side effects while still controlling the cancer.
This trial tests a new treatment for advanced nasopharyngeal cancer. You will get chemotherapy and radiation, followed by maintenance therapy with an immunotherapy drug called toripalimab to help your immune system fight the cancer.
Hear when a new Nasopharyngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.